This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Original articles
Dorr RT, Alberts DS: Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Invest New Drugs 1: 151–159, 1983.
Secondary literature
Gain M, Melzer S, Meyer-Jürshof A, et al: Teniposid: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 3: 34, 1998.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.
Bokemeyer C: Dermatoxizität antineoplastischer Substanzen. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1411–1426, 1999.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Root T: Investigational drugs: teniposide. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 384–386, 1997.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Bristol-Myers Squibb, personal communication, January 1999.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) Zytostatika Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.
Summary of product characteristics Vumon (Austria), Bristol-Myers Squibb, January 1997.
Further reading
Lorenz W, Reimann HJ, Schmal A, et al: Histamine release in dogs by Cremophor® EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Teniposide. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_46
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3710-9_46
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3712-3
Online ISBN: 978-3-7091-3710-9
eBook Packages: Springer Book Archive